APA (7th ed.) Citation

Lyrarakis, G., Bouros, S., Anastasopoulou, A., Gkoufa, A., Diamantopoulos, P., Gogas, H., & Ziogas, D. Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. Elsevier.

Chicago Style (17th ed.) Citation

Lyrarakis, G., S. Bouros, A. Anastasopoulou, A. Gkoufa, P. Diamantopoulos, H. Gogas, and D. Ziogas. Immunotherapy After Progression to Immunotherapy: Pembrolizumab and Lenvatinib Versus Conventional Chemotherapy for Patients with Metastatic Melanoma After Failure of PD-1/CTLA-4 Inhibition. Elsevier.

MLA (9th ed.) Citation

Lyrarakis, G., et al. Immunotherapy After Progression to Immunotherapy: Pembrolizumab and Lenvatinib Versus Conventional Chemotherapy for Patients with Metastatic Melanoma After Failure of PD-1/CTLA-4 Inhibition. Elsevier.